G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
08 août 2024 06h30 HE
|
G1 Therapeutics
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
Pharmacosmos Group to Acquire G1 Therapeutics
07 août 2024 06h29 HE
|
G1 Therapeutics; Pharmacosmos
Pharmacosmos Group to Acquire G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 août 2024 18h50 HE
|
G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
25 juil. 2024 11h15 HE
|
G1 Therapeutics
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business
Update on August 8, 2024
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
01 juil. 2024 08h00 HE
|
G1 Therapeutics
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
24 juin 2024 06h30 HE
|
G1 Therapeutics
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negativ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juin 2024 07h00 HE
|
G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
28 mai 2024 06h30 HE
|
G1 Therapeutics
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 ADC
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
23 mai 2024 17h06 HE
|
G1 Therapeutics
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
22 mai 2024 10h00 HE
|
G1 Therapeutics
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit